These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 37166263)

  • 1. Therapeutic perspective: evolving evidence of nonsteroidal mineralocorticoid receptor antagonists in diabetic kidney disease.
    Yao L; Liang X; Wang P
    Am J Physiol Endocrinol Metab; 2023 Jun; 324(6):E531-E541. PubMed ID: 37166263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease.
    Lerma E; White WB; Bakris G
    Postgrad Med; 2023 Apr; 135(3):224-233. PubMed ID: 35392754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renoprotective Effects of Mineralocorticoid Receptor Antagonists Against Diabetic Kidney Disease.
    Bayne S; LeFevre J; Olstinske K; Ravindran S; Munusamy S
    Adv Biol (Weinh); 2024 Mar; 8(3):e2300496. PubMed ID: 38065929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective.
    Marzolla V; Infante M; Armani A; Rizzo M; Caprio M
    Expert Opin Drug Saf; 2022 Sep; 21(9):1161-1170. PubMed ID: 36174659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aldosterone, Mineralocorticoid Receptor Activation, and CKD: A Review of Evolving Treatment Paradigms.
    Epstein M; Kovesdy CP; Clase CM; Sood MM; Pecoits-Filho R
    Am J Kidney Dis; 2022 Nov; 80(5):658-666. PubMed ID: 36057467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical effect of nonsteroidal mineralocorticoid receptor (MR) antagonists in the treatment of diabetic kidney disease: expectations as a new therapeutic strategy.
    Sato A; Nishimoto M
    Hypertens Res; 2022 Aug; 45(8):1310-1321. PubMed ID: 35726084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiorenal benefits of mineralocorticoid antagonists in CKD and type 2 diabetes : Lessons from the FIGARO-DKD trial.
    Haller H
    Herz; 2022 Oct; 47(5):401-409. PubMed ID: 36094559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease.
    Kim DL; Lee SE; Kim NH
    Endocrinol Metab (Seoul); 2023 Feb; 38(1):43-55. PubMed ID: 36891650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiorenal benefits of finerenone: protecting kidney and heart.
    González-Juanatey JR; Górriz JL; Ortiz A; Valle A; Soler MJ; Facila L
    Ann Med; 2023 Dec; 55(1):502-513. PubMed ID: 36719097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular and Renal Benefit of Novel Non-steroidal Mineralocorticoid Antagonists in Patients with Diabetes.
    Kintscher U
    Curr Cardiol Rep; 2023 Dec; 25(12):1859-1864. PubMed ID: 37991625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects.
    Barrera-Chimal J; Lima-Posada I; Bakris GL; Jaisser F
    Nat Rev Nephrol; 2022 Jan; 18(1):56-70. PubMed ID: 34675379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium-glucose cotransporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin-angiotensin system blockade.
    Shenoy SV; Nagaraju SP; Bhojaraja MV; Prabhu RA; Rangaswamy D; Rao IR
    Nephrology (Carlton); 2021 Nov; 26(11):858-871. PubMed ID: 34176194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus.
    Wish JB; Pergola P
    Mayo Clin Proc Innov Qual Outcomes; 2022 Dec; 6(6):536-551. PubMed ID: 36277502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mineralocorticoid Antagonism and Diabetic Kidney Disease.
    Lytvyn Y; Godoy LC; Scholtes RA; van Raalte DH; Cherney DZ
    Curr Diab Rep; 2019 Jan; 19(1):4. PubMed ID: 30673886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
    Yang S; Zhao L; Mi Y; He W
    Diabetes Obes Metab; 2022 Nov; 24(11):2159-2168. PubMed ID: 35712807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonsteroidal mineralocorticoid antagonists in diabetic kidney disease.
    Dojki FK; Bakris G
    Curr Opin Nephrol Hypertens; 2017 Sep; 26(5):368-374. PubMed ID: 28771453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Kidney Disease: Their Application in the Era of SGLT2 Inhibitors and GLP-1 Receptor Agonists.
    Cohen S; Sternlicht H; Bakris GL
    Curr Diab Rep; 2022 May; 22(5):213-218. PubMed ID: 35441935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Narrative Review of Diabetic Kidney Disease: Previous and Current Evidence-Based Therapeutic Approaches.
    Mima A
    Adv Ther; 2022 Aug; 39(8):3488-3500. PubMed ID: 35751762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of a novel nonsteroidal selective mineralocorticoid receptor antagonist, esaxerenone (CS-3150), on blood pressure and renal injury in high salt-treated type 2 diabetic mice.
    Bhuiyan AS; Rafiq K; Kobara H; Masaki T; Nakano D; Nishiyama A
    Hypertens Res; 2019 Jun; 42(6):892-902. PubMed ID: 30664703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Therapies in Diabetic Kidney Disease and Risk of Hyperkalemia: A Review of the Evidence From Clinical Trials.
    Albakr RB; Sridhar VS; Cherney DZI
    Am J Kidney Dis; 2023 Dec; 82(6):737-742. PubMed ID: 37517546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.